Matinas BioPharma Holdings (MTNB) Net Income towards Common Stockholders (2014 - 2026)
Matinas BioPharma Holdings (MTNB) reported Net Income towards Common Stockholders of -$1.9 million for Q1 2026, down 16.0% year-over-year from -$2.3 million in Q1 2025, and little changed quarter-over-quarter from -$1.9 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$1.9 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$1.9 million, down 16.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.8 million (up 61.29% YoY), and the FY2025 annual result was -$11.0 million, up 54.79% from the prior year.
- Net Income towards Common Stockholders held at -$1.9 million in Q1 2026 per MTNB's latest filing, from -$1.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$1.7 million in Q1 2025 and troughed at -$8.4 million in Q4 2024.
- A 5-year average of -$4.6 million and a median of -$5.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders plunged 61.97% in 2023, then surged 77.33% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.6 million in 2022, then tumbled by 61.97% to -$5.9 million in 2023, then plunged by 43.25% to -$8.4 million in 2024, then surged by 77.33% to -$1.9 million in 2025, then fell by 0.47% to -$1.9 million in 2026.
- Business Quant data shows MTNB's Net Income towards Common Stockholders at -$1.9 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.92 Mn |
| Dec 31, 2025 | -1.91 Mn |
| Sep 30, 2025 | -2.15 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Sep 30, 2024 | -4.28 Mn |
| Jun 30, 2024 | -5.84 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -6.13 Mn |
| Jun 30, 2023 | -6.16 Mn |
| Mar 31, 2023 | -5.59 Mn |
| Dec 31, 2022 | -3.63 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -5.92 Mn |
| Mar 31, 2022 | -5.98 Mn |
| Dec 31, 2021 | -6.70 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -4.98 Mn |